Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity

US7323466B2 · kind B2 · utility

Assignees

• Hoffmann-La Roche Inc. · US
• Vernalis Research Limited · GB

Inventors

• Jonathan Mark Bentley · Wokingham, GB
• Claire Elizabeth Dawson · Wokingham, GB
• Wolfgang Guba · Memmingen, DE
• Paul Hebeisen · Basel, CH
• Nathaniel Julius Thomas Monck · Abingdon, GB
• Robert Mark Pratt · Wokingham, GB
• Hans Richter · Weil am Rhein, DE
• Stephan Roever · Inzlingen, DE
• Vicki Ruston · Wokingham, GB

Key dates

• Filing date: Jan 13, 2006
• Grant date: Jan 29, 2008
• Expiry date: May 5, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention refers to chemical compounds of formula (I)as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1. These compounds can be used for the preparation of medicaments.